Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors.
The leading cause of end-stage renal disease (ESRD) is diabetic nephropathy. Interventions that prevent or palliate renal disease have a positive impact by improving patient care and diminishing healthcare costs. The following review summarizes clinical trals that evaluated treatment in various patient populations including Type 2 diabetic patients with microalbuminuria, subjects with proteinuric non-diabetic nephropathies, and Type 1 and Type 2 diabetic patients with overt nephropathy. These clinical trials have demonstrated that agents directly affecting the renin-angiotensin-aldosterone system provide renal protection beyond that attributable to blood pressure control.
Brenner
Barry M
BM
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. bmbrenner@bics.bwh.harvard.edu
Zagrobelny
Joann
J
D057912:Angiotensin II Type 2 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control*
D057912:Angiotensin II Type 2 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents